Get the Stockscreener App
6.03
0.99%
-0.06
After Hours:
6.13
0.10
+1.66%
Valneva Se Adr stock is traded at $6.03, with a volume of 87,155.
It is down -0.99% in the last 24 hours and down -43.17% over the past month.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
See More
Previous Close:
$6.09
Open:
$6.27
24h Volume:
87,155
Relative Volume:
1.42
Market Cap:
$523.87M
Revenue:
$196.47M
Net Income/Loss:
$-132.90M
P/E Ratio:
-3.8741
EPS:
-1.5565
Net Cash Flow:
$-97.72M
1W Performance:
-3.52%
1M Performance:
-43.17%
6M Performance:
-42.57%
1Y Performance:
-14.47%
1-Day Range:
$6.00
$6.31
1-Week Range:
$5.92
$6.4199
52-Week Range:
$5.4289
$12.25
Valneva Se Adr Stock (VALN) Company Profile
Compare VALN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VALN
Valneva Se Adr
|
6.03 | 529.08M | 196.47M | -132.90M | -97.72M | -1.5565 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Valneva Se Adr Stock (VALN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Resumed | H.C. Wainwright | Buy |
| Aug-03-22 | Initiated | H.C. Wainwright | Buy |
Valneva Se Adr Stock (VALN) Latest News
VALN stock nosedives on mixed results from Lyme disease vaccine study - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SEVALN - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
VLA.PA Technical Analysis | Trend, Signals & Chart Patterns | VALNEVA SE (EPA:VLA) - ChartMill
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Valneva Faces Mounting Legal Pressure Following Clinical Trial Setback - AD HOC NEWS
2026-04-06 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Shareholders to Learn More About the Investigation | NDAQ:VALN | Press Release - Stockhouse
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Valneva's Travel Vaccines: Strategic Pivot to Emerging Markets Drives Long-Term Investor Value in Bi - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Declaration of shares and voting rights of Valneva SE – March 2026 - GlobeNewswire Inc.
Valneva SE Under Investigation for Securities Fraud - Intellectia AI
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Investors to Connect - ACCESS Newswire
Valneva (NASDAQ:VALN) Shares Gap UpShould You Buy? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Valneva (NASDAQ:VALN) Sees Large Volume IncreaseHere's Why - MarketBeat
Short Interest in Valneva SE Sponsored ADR (NASDAQ:VALN) Rises By 25.4% - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Stockholders to Connect - ACCESS Newswire
2026-03-27 | Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:VALN | Press Release - Stockhouse
VLA.PA Stock Price, Quote & Chart | VALNEVA SE (EPA:VLA) - ChartMill
Valneva, Venture Global And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN - FinancialContent
VALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine Study - Yahoo Finance
VALN Shares Plunge Following Uncertain Outcomes in Lyme Disease Vaccine Trial - Bitget
Jefferies reiterates Valneva stock Buy rating after Lyme trial data - Investing.com
HC Wainwright Has Positive Forecast for Valneva Q3 Earnings - MarketBeat
Valneva (NASDAQ:VALN) Shares Gap Down – Here’s Why - Defense World
FY2030 Earnings Forecast for Valneva Issued By HC Wainwright - Defense World
Valneva (NASDAQ:VALN) Shares Gap DownHere's What Happened - MarketBeat
FY2030 Earnings Estimate for Valneva Issued By HC Wainwright - MarketBeat
Earnings call transcript: Valneva SE Q4 2025 sees EPS beat, stock rises - Investing.com Canada
[20-F] Valneva SE Files Annual R... | VALN SEC FilingForm 20-F - Stock Titan
Valneva SE earnings beat by $0.13, revenue topped estimates - Investing.com India
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study - MSN
Valneva (NASDAQ:VALN) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Valneva (NASDAQ:VALN) Trading Up 7.1%Here's What Happened - MarketBeat
Valneva Se Adr Stock (VALN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):